Figure 3

Prognostic significance of BCL2 according to hormonal status, HER2 status and adjuvant therapy. Kaplan–Meier curves of cumulative survival according to (A) BCL2 status: (i) BCL2−, HR=1.00; (ii) BCL2+, HR=0.76, 95% CI 0.66–0.88, P<0.001. (B) Oestrogen receptor and BCL2 status: (i) ER−/BCL2−, HR=1.00; (ii) ER+/BCL2−, HR=0.81, 95% CI 0.69–0.96, P=0.012; (iii) ER−/BCL2+, HR=0.62, 95% CI 0.53–0.71, P<0.001; (iv) ER+/BCL2+, HR=0.46, 95% CI 0.42–0.51, P<0.001. (C) Human epidermal growth factor receptor 2 and BCL2 status: (i) HER2−/BCL2−, HR=1.00; (ii) HER2+/BCL2−, HR=1.36, 95% CI 1.17–1.59, P<0.001; (iii) HER2−/BCL2+, HR=0.55, 95% CI 0.49–0.61, P<0.001; (iv) HER2+/BCL2+; n=399, HR=0.94, 95% CI 0.78–1.13, P=0.52. (D) Triple-negative phenotype (TNP) and BCL2 status: (i) non-TNP/BCL2−, HR=1.00; (ii) TNP/BCL2−, HR=1.43, 95% CI 1.18–1.74, P<0.001; (iii) non-TNP/BCL2+, HR=0.56, 95% CI 0.49–0.65, P<0.001; (iv) TNP/BCL2+, HR=1.19, 95% CI 0.83–1.73, P=0.34. (E) Adjuvant chemotherapy and BCL2 status: (i) adjuvant chemotherapy/BCL2−, HR=1.00; (ii) adjuvant chemotherapy/BCL2+, HR=0.76, 95% CI 0.71–0.82, P<0.001. (F) Adjuvant endocrine therapy and BCL2 status: (i) adjuvant endocrine therapy/BCL2−, HR=1.00; (ii) adjuvant endocrine therapy/BCL2+, HR=0.69, 95% CI 0.64–0.75, P<0.001.